<DOC>
	<DOCNO>NCT01692834</DOCNO>
	<brief_summary>To compare bioavailability , pharmacokinetic profile tolerability two formulation intravenous cyclosporine healthy volunteer .</brief_summary>
	<brief_title>A Study Compare Bioavailability Pharmacokinetics Cyclosporine After Intravenous Administration NEUROSTAT® , CREMOPHOR® EL-free Lipid Emulsion , SANDIMMUNE® Injection ( Suspension Cyclosporine CREMOPHOR® EL ) Healthy Volunteers</brief_title>
	<detailed_description>Participants randomize two treatment sequence : test product follow reference product vice versa . There washout period set 14-21 day first second treatment period . Through indwell IV cannula , subject receive either 5 mg/kg NeuroSTAT® ( test ) 5 mg/kg Sandimmune® ( reference ) , infuse constant rate 4 h syringe pump . A total 22 blood sample Cyclosporine analysis obtain pre-dose pre specify time point last sample 48 h start infusion .</detailed_description>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>1 . Healthy male female subject 18 &lt; 56 year age . 2 . Caucasian NonCaucasian subject . 3 . Body mass within 15 % ideal mass relation height age ( relate Body Mass Index [ BMI ] 19 33 kg/m2 ) . 4 . Body mass le 60 kg 100 kg . 5 . Findings within range clinical acceptability medical history physical examination , laboratory result within laboratory reference range relevant laboratory test ( unless investigator consider deviation irrelevant purpose study ) . 6 . Normal 12lead ECG vital sign , abnormality investigator consider disqualification participation study . 7 . Willingness undergo pre , interim poststudy physical examination , vital sign laboratory investigation . 8 . Ability comprehend willingness sign statement inform consent ( screen periodrelated procedure ) . 9 . Nonsmoker past smoker stop use form tobacco , include snuff similar product , least 3 month first administration study medication . 10 . Female subject childbearing potential , pregnant , lactate either abstain sexual activity use medically acceptable reliable method contraception duration study . Examples reliable method contraception include tubal ligation , hysterectomy , intrauterine device , barrier method combine spermicide . The use hormonal contraceptive ( include hormonal intrauterine device ) allow . Females childbearing potential may include menstrual period one year consider postmenopausal . A pregnancy test perform prior cyclosporine dose woman childbearing potential . 1 . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limited validity consent participate study limit ability comply protocol requirement . 2 . History , current compulsive alcohol abuse ( &gt; 10 drink weekly ) , regular exposure substance abuse . 3 . Use medication , prescribed overthecounter , within 2 week prior first administration study medication ( within 2 week prior dose Treatment period 2 Cohort 2 ) except would affect outcome study opinion investigator . 4 . Females take oral transdermal hormonal contraceptive within 14 day precede dose use implant injected hormonal contraceptive within 6 month prior dose . 5 . Participation another study experimental drug , last administration ( previous study medication ) within 12 week first administration study medication . 6 . Treatment within previous 3 month drug welldefined potential adversely affect major organ system . 7 . A major illness 3 month commencement screening period . 8 . History hypersensitivity study medication , carrier substance , related medication . 9 . History type malignancy . 10 . Tendency toward recurrent infection , know untreated parasitic infection , history primary secondary immunodeficiency . 11 . History allergy soybean soy product . 12 . History allergy egg egg product . 13 . History bronchial asthma bronchospastic disease . 14 . History epilepsy . 15 . History porphyria . 16 . History psoriasis . 17 . History atopic dermatitis . 18 . History elevate cholesterol level 6.5 mmol/L . 19 . History gout . 20 . History rheumatoid arthritis . 21 . History evidence kidney disease renal failure . 22 . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . 23 . Total bilirubin concentration , exceed 10 % normal laboratory range ( 430 μmol/L ) . 24 . Donation loss blood equal exceed 500 mL 8 week first administration study medication . 25 . Diagnosis hypotension make screening period . 26 . Diagnosis hypertension make screening period current diagnosis hypertension . 27 . Resting pulse rate &gt; 100 beat per minute &lt; 40 beat per minute screening period , either supine standing . 28 . Positive test HIV Hepatitis B and/or Hepatitis C. 29 . Positive urine screen drug abuse . 30 . Positive urine screen tobacco use . 31 . A serum pregnancy test female ( beta human chorionic gonadotropin [ βHCG ] ) either positive perform lactation . 32 . Vaccination vaccine ( include live , attenuate virus bacterial vaccine ) within 4 week first dose plan vaccination within 3 month second dose . 33 . Subjects close family member ( spouse/partner/children ) receive live vaccine study , within 3 month second dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>ciclosporin</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>Sandimmune</keyword>
	<keyword>Sandimmun</keyword>
	<keyword>CicloMulsion</keyword>
	<keyword>NeuroSTAT</keyword>
</DOC>